[The efficacy and safety of intravenous sucrose iron therapy for recurrent iron deficiency anemia].

• DOI: 10.3760/cma.j.issn.0253-2727.2023.05.009
• Publication Date: 2023-05-14
• Authors: J Q Liu; Xin Yang; X Liu; Jing Hu; Xiangrong Hu; X X Li; Y Zhao; Yuhang Shi; B H Zhang; W R Yang; Guangxin Peng; Xin Zhao; F K Zhang
• Keywords: Iron sucrose

Objective: To evaluate the efficacy and safety of intravenous iron supplementation in patients with recurrent deficiency anemia (IDA) . Methods: This retrospective analysis 90 IDA from May 2012 to December 2021 was conducted, comparing therapy group oral group. Results: Among IDA, 20 were males 70 females, a median age 40 (range: 14-85) years. A total 60 received 30 supplementation. The hematologic response rates significantly higher than those at 4 8 weeks after treatment [80.0% (48/60) vs 3.3% (1/30) 96.7% (58/60) 46.7% (14/30), all P<0.001, respectively]. increase hemoglobin levels also [38 (4, 66) g/L 7 (1, 22) week 44.5 (18, 80) 19 (3, 53) 8, P<0.001]. had proportion who achieved normal (55.0% 0 90% 43.3%, respectively). Iron metabolism indicators tested before 26 groups, respectively. serum ferritin (SF) 113.7 (49.7, 413.5) μg/L, 54% (14/26) these SF ≥100 which [14.0 (5.8, 84.2) t=4.760, P<0.001] μg/L (P=0.013). incidence adverse reactions (2/60) group, lower that [20.0% (6/30), P=0.015]. Conclusion: Intravenous is more effective for response, faster increase, storage replenishment compared it well tolerated by patients.目的： 评估静脉铁剂治疗复发性缺铁性贫血（IDA）的有效性和安全性。 方法： 回顾性分析2012年5月至2021年12月期间90例复发性IDA患者的临床资料，比较静脉铁剂组与口服铁剂组的疗效及不良反应发生情况。 结果： 90例复发性IDA患者中，男20例，女70例，中位年龄40（14，85）岁。60例接受静脉铁剂治疗，30例接受口服铁剂治疗。补铁治疗后第4、8周，静脉铁剂组血液学反应率分别为80.0%（48/60）、96.7%（58/60），显著高于口服铁剂组患者的3.3%（1/30）、46.7%（14/30）（Fisher，均P<0.001）；HGB较基线分别中位增高38（4，66）g/L和44.5（18，80）g/L，显著高于口服铁剂组的7（1，22）g/L和19（3，53）g/L（t=10.720，P<0.001；t=7.392，P<0.001）；HGB恢复正常患者分别为33例（55.0%）和54例（90.0%），显著高于口服铁剂组的0例和13例（43.3%）（Fisher，均P<0.001）。静脉铁剂组和口服铁剂组分别有26例和7例在治疗前以及治疗后8周检测了铁代谢指标。治疗后8周静脉铁剂组血清铁蛋白（SF）中位增高值113.7（49.7，413.5）μg/L，53.8%（14/26）的患者血清SF≥100 μg/L，显著高于口服铁剂组的14.0（5.8，84.2）μg/L（t=4.760，P<0.001），而口服铁剂组则未有SF≥100 μg/L患者（Fisher，P=0.013）。静脉铁剂组不良反应率为3.3%（2/60），远低于口服铁剂组20.0%（6/30）（Fisher，P=0.015）。 结论： 复发性IDA应用静脉补铁较口服补铁治疗血液学反应率更高，HGB上升更快，储存铁补足率更高，患者耐受良好。.